Back to Screener

Healthcare

China Medical & HealthCare Group Limited(COLRF)

Live Price

Offline

$0.08

+0.00% today

1Y Change

+0.00%

Window

Jun 26, 2025 โ†’ Jun 18, 2026

Market Cap
$1.13B
Revenue Growth
+3.7%
EPS Growth
+117.2%
Dividend Yield
1.9%

Coverage: 246 bars ยท Jun 26, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

China Medical & HealthCare Group Limited (COLRF) is a Healthcare stock with a market cap of $1.13B and listed on OTC. The stock last traded around $0.08 and up 0.0% across the available one-year price window (Jun 26, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of +3.7%, EPS growth of +117.2%, a dividend yield of 1.9%. What stands out right now is revenue +3.7%, EPS +117.2%, free cash flow -155.0% with operating margin 3.8% and ROIC 1.8%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Stock Foundry combines COLRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

COLRF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

COLRF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

COLRF Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for COLRF and SPY.

Calendar-year return history is still loading or unavailable.

Financial profile

China Medical & HealthCare Group Limited (COLRF)

Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.

FY Revenue

$1.2B

-17.7% YoY

FY Net Income

-$111.9M

+18.5% YoY

Free Cash Flow

-$114.5M

-275.9% YoY

Revenue Growth

+3.7%

EPS Growth

+117.2%

Gross Margin

13.8%

Net Margin

-1.6%

Income statement

HKD

Annual
Metric20242023202220212020
Revenue1.6B1.6B1.4B1.5B1.2B
Gross Profit325M286M162M176M125M
Operating Income86M83M-39M-21M-13M
EBITDA183M175M47M52M70M
Net Income29M11M-124M-137M-112M
EPS (Diluted)โ€”โ€”โ€”โ€”โ€”

Balance sheet

HKD

Point-in-time
Metric20242023202220212020
Cash & Equivalents885M890M614M637M650M
Total Assets3.5B3.6B3.2B3.5B3.4B
Total Liabilities1.6B1.7B1.7B1.8B1.6B
Shareholder Equity1.8B1.9B1.6B1.7B1.8B
Total Debt836M799M979M972M974M
Net Debt-49M-92M365M335M324M

Cash flow positioning

Latest Full Year

Operating Cash Flow

14M

-106.4% YoY

Capital Expenditures

100M

+35.0% YoY

Free Cash Flow

114M

-275.9% YoY

Key ratios

  • Gross Margin

    13.8%

  • Operating Margin

    3.8%

  • Net Margin

    -1.6%

  • ROE

    -1.5%

  • Debt / Equity

    0.50x

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.